126 related articles for article (PubMed ID: 35764491)
1. Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis.
Naser AY; Ofori-Asenso R; Awawdeh SA; Qadus S; Alwafi H; Liew D
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):760-773. PubMed ID: 35764491
[TBL] [Abstract][Full Text] [Related]
2. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
[TBL] [Abstract][Full Text] [Related]
3. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
Dashputre AA; S Gatwood K; Schmidt J; Gatwood J
J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
[TBL] [Abstract][Full Text] [Related]
4. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Lee C; Grigorian M; Nolan R; Binder G; Rice G
J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
[TBL] [Abstract][Full Text] [Related]
6. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications.
Cross AJ; Elliott RA; Petrie K; Kuruvilla L; George J
Cochrane Database Syst Rev; 2020 May; 5(5):CD012419. PubMed ID: 32383493
[TBL] [Abstract][Full Text] [Related]
7. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
[TBL] [Abstract][Full Text] [Related]
9. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
Cao Y; Wan N; Liang Z; Xie J; Wang S; Lin T; Zhang T; Jiang J
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e478-e488. PubMed ID: 31130487
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.
Mark T; Falkenstein A; Kish J
Future Oncol; 2022 Feb; 18(5):553-564. PubMed ID: 34787472
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.
Ononogbu O; Akindele O; Yazdanfard S; Fatima B; Abughosh S; Trivedi MV
Support Care Cancer; 2024 Jun; 32(7):407. PubMed ID: 38833106
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Anderson SM; Beck B; Sterud S; Lockhorst R; Ngorsuraches S
J Oncol Pharm Pract; 2019 Jun; 25(4):806-812. PubMed ID: 29486638
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.
Lyu WW; Zhao QC; Song DH; Zhang JJ; Ding ZX; Li BY; Wei CM
Chin Med J (Engl); 2016 Feb; 129(3):320-5. PubMed ID: 26831235
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Mian H; Fiala M; Wildes TM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
[TBL] [Abstract][Full Text] [Related]
17. Adherence and Discontinuation of Disease-Specific Therapies for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Qadus S; Naser AY; Ofori-Asenso R; Ademi Z; Al Awawdeh S; Liew D
Am J Cardiovasc Drugs; 2023 Jan; 23(1):19-33. PubMed ID: 36434365
[TBL] [Abstract][Full Text] [Related]
18. Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting.
Santoleri F; Lasala R; Ranucci E; Rocchi M; Pulini S; Morelli AM; Spadano A; Costantini A
J Oncol Pharm Pract; 2022 Jan; 28(1):24-30. PubMed ID: 33349148
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
